XBI250425C69000
- 7.14
- 0.000.00%
SPDR S&P Biotech ETF Newsroom
12 Health Care Stocks Moving In Friday's After-Market Session
Catalyst Watch: Apple, Amazon & Microsoft's Earnings Confessions, Meta's LlamaCon and the Jobs Report
How Is The Market Feeling About Gilead Sciences?
'Amgen Pledges $900 Million, Hundreds of Jobs in Ohio Expansion'- Bloomberg
If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today
4 Stocks to Watch on Friday: GILD, ABBV, CL and SLB
Needham Reiterates Hold on Gilead Sciencesto Hold
Gilead Sciences Analyst Ratings
Skechers Posts Weak Revenue, Joins Intel, Gilead Sciences And Other Big Stocks Moving Lower In Friday's Pre-Market Session
This United Therapeutics Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Friday
Why Coursera Shares Are Trading Higher By Over 7%; Here Are 20 Stocks Moving Premarket
Alphabet, Intel And 3 Stocks To Watch Heading Into Friday
Gilead Sciences Declares $0.79 Dividend
Earnings Call Summary | Gilead Sciences(GILD.US) Q1 2025 Earnings Conference
Gilead Sciences Highlights Potential FDA Approval for Lenacapavir in June 2025
Gilead Sciences Stock Slips After Mixed Q1 Results, Lowered FY25 EPS Guidance
Gilead Sciences in Charts: Revenue From HIV Product Sales Grows Most Among Segments in Q1
Neurocrine Biosciences Publishes Positive Data From Movement Disorder Study
Neurocrine Announces Publication Of Post-Hoc Analysis From Two 48-Week Studies, KINECT 3 Extension And KINECT 4, Demonstrating Long-term Safety Profile And Robust Efficacy Of INGREZZA Capsules In Adults With TD In The Journal Of Clinical Psychiatry
Gilead Sciences Non-GAAP EPS of $1.81 Beats by $0.04, Revenue of $6.67B Misses by $140M